# Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer

> **NCT07419932** · — · RECRUITING · sponsor: **Fujian Medical University** · enrollment: 120 (estimated)

## Conditions studied

- Thyroid Cancer
- Thyroid Neoplasms

## Interventions

- **DRUG:** Multitarget Tyrosine Kinase Inhibitors
- **DRUG:** BRAF inhibitor dabrafenib and MEK inhibitor trametinib
- **DRUG:** RET Inhibitor
- **DRUG:** PD(L)-1 inhibitor
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Surgery
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT07419932
- **Lead sponsor:** Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-23
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-06-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07419932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07419932, "Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07419932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*